HESTERBIO · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 57/100 — Quality 61 · Valuation 47 · Momentum 64
| Share price | ₹2,523.40 |
| Market cap | ₹1,804 Cr |
| P/E ratio | 32.5 |
| P/B ratio | 5.0 |
| ROE | 18.8% |
| ROCE | 15.8% |
| Dividend yield | 0.52% |
| Book value | ₹423.46 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹333 Cr | ₹57 Cr | 26.0% |
| 2025 | ₹311 Cr | ₹29 Cr | 20.0% |
| 2024 | ₹305 Cr | ₹21 Cr | 18.0% |
| 2023 | ₹266 Cr | ₹28 Cr | 19.0% |
| 2022 | ₹235 Cr | ₹39 Cr | 26.0% |
Hester Biosciences Limited manufactures and trades in veterinary vaccines and health products in India and internationally. It operates through two segments, Poultry Healthcare and Animal Healthcare. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal, fowl pox, marek's disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis. It also offers vaccines for peste des petits ruminants, goat pox, brucella, lumpy skin disease, contagious bovine pleuropneumonia, and contagious caprine pleuropneumoni